Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Zura Bio ( (ZURA) ) has shared an announcement.
On May 20, 2025, Zura Bio announced the launch of TibuSHIELD, a global Phase 2 study to evaluate tibulizumab in adults with moderate to severe hidradenitis suppurativa (HS). This study, which began with the activation of its first clinical site, is the first to assess dual inhibition of BAFF and IL-17A pathways in HS patients. The study will enroll approximately 180 participants across the United States, Canada, and Europe, with results expected in the third quarter of 2026. The launch of TibuSHIELD marks a significant step in Zura Bio’s mission to develop differentiated therapies for severe inflammatory diseases, following a similar study for systemic sclerosis initiated in December 2024.
The most recent analyst rating on (ZURA) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.
Spark’s Take on ZURA Stock
According to Spark, TipRanks’ AI Analyst, ZURA is a Neutral.
Zura Bio’s overall stock score is driven by significant financial challenges, including no revenue generation and consistent losses despite a strong cash position and no debt. While technical indicators suggest some short-term bullish trends, the negative P/E ratio and lack of dividends underscore the valuation concerns. The company’s ability to generate revenue and improve operational efficiency will be crucial for future performance.
To see Spark’s full report on ZURA stock, click here.
More about Zura Bio
Zura Bio is a clinical-stage, multi-asset immunology company focused on developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs. Their pipeline includes product candidates targeting key immune system mechanisms to enhance efficacy, safety, and dosing convenience.
Average Trading Volume: 364,467
Technical Sentiment Signal: Sell
Current Market Cap: $66.82M
Find detailed analytics on ZURA stock on TipRanks’ Stock Analysis page.